<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956188</url>
  </required_header>
  <id_info>
    <org_study_id>Omega 3 and SLE and APS USP</org_study_id>
    <nct_id>NCT01956188</nct_id>
  </id_info>
  <brief_title>Omega 3 in LES and APS</brief_title>
  <official_title>Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been demonstrated that EPA and DHA supplementation may have anti-inflammatory
      properties in several chronic diseases, namely, diabetes, obesity, and in rheumatoid
      arthritis, although not with controversy. Systemic lupus erythematosus (SLE) and
      Antiphospholipid Antibody Syndrome (AAS) are autoimmune diseases characterized by a chronic
      inflammatory state which is associated with the disease´s clinical symptoms. Thus, we
      hypothesized that EPA and DHA supplementation may beneficially affect the inflammatory
      cytokine profile and clinical features of LES and AAS patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine profile (serum levels of IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-alpha, IFN-y)</measure>
    <time_frame>4 months</time_frame>
    <description>Cytokines´ serum levels (pg/ml) will be assessed by Elisa kits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>4 months</time_frame>
    <description>Endothelial function assessed by flow mediated dilatation (FMD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clical features</measure>
    <time_frame>4 months</time_frame>
    <description>Disease activity - assessed by SLEDAI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical features</measure>
    <time_frame>4 months</time_frame>
    <description>Quality of life - assessed by SF-36 questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical features</measure>
    <time_frame>4 months</time_frame>
    <description>Fatigue - assessed by 2 questionaires - Chalders´Fatigue Scale and Fatigue Severity Scale (FSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical features</measure>
    <time_frame>4 months</time_frame>
    <description>Body composition - lean (Kg) and fat mass (Kg) assessed by air displacement pletysmography (BOD POD).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Primary Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>EPA and DHA supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPA (1800mg/d) and DHA (1200mg/d) supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soy oil (3000 mg/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA and DHA supplementation</intervention_name>
    <description>Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.</description>
    <arm_group_label>EPA and DHA supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be given 3g/d of soy oil - 5 capsules per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Age between 7 and 40 years

        Exclusion Criteria:

          -  Cardiovascular dysfunction

          -  Rhythm and conduction disorders

          -  Musculoskeletal disturbances

          -  Kidney and pulmonary involvements

          -  Peripheral neuropathy

          -  Use of tobacco

          -  Treatment with lipid-lowering or hypoglycemic drugs

          -  Fibromyalgia

          -  Use of chronotropic or antihypertensive drugs

          -  Physically active subjects
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital - University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05.403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Fabiana Braga Benatti</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

